EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance

Ranjit S Samra iD, Erica L Plummer iD, Lenka A Vodstrcil iD, Ivette Aguirre, Emily J Clarke iD, Christopher K Fairley, Eric P F Chow, Catriona S Bradshaw iD

Open Forum Infectious Diseases · 01.12.2023 · 10 (12)

DOI: 10.1093/ofid/ofad590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 22.11.2023. Verfasst von Ranjit S Samra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: (NHMRC) Leadership Investigator, NHMRC Emerging Leadership Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance in Mycoplasma genitalium is rising globally and antimicrobial options are limited. We evaluated the efficacy of sitafloxacin regimens for macrolide-resistant M genitalium at Melbourne Sexual Health Centre, Australia, between January 2017 and February 2022. Before June 2017, patients received doxycycline followed by sitafloxacin; subsequently, patients received doxycycline followed by combined doxycycline + sitafloxacin. Of 229 patients treated with a sitafloxacin regimen, 80.6% experienced microbial cure. Sitafloxacin cured 94.2% of infections that had not previously failed moxifloxacin and 69.5% of infections that had; prior failure of moxifloxacin was associated with an 8-fold odds of sitafloxacin failure. There was no difference in cure between sequential monotherapy and combination therapy when patients were stratified by past failure of moxifloxacin (P > .05); however, small numbers limited comparisons. Sitafloxacin was well tolerated and still achieved 70% cure in patients in whom moxifloxacin had failed. These data highlight the benefit of incorporating relevant fluoroquinolone resistance markers into assays to assist clinical decision making.

Schlagwörter

Stichwörter der Autor:innen

Mycoplasma genitaliumantibacterial agentsfluroquinolonessexually transmitted infectionssitafloxacin

Autor:innen und Institutionen

  • Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia.
  • Department of Infectious Diseases, Alfred Hospital, Alfred Health, Melbourne, Victoria, Australia.
  • Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Ranjit S Samra, Erica L Plummer, Lenka A Vodstrcil, Emily J Clarke, Catriona S Bradshaw

Förderung

  • (NHMRC) Leadership Investigator
  • NHMRC Emerging Leadership Investigator

Zitieren

APA

Samra, R. S., Plummer, E. L., Vodstrcil, L. A., Aguirre, I., Clarke, E. J., Fairley, C. K., Chow, E. P. F., & Bradshaw, C. S. (2023). Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance. Open Forum Infectious Diseases, 10(12). https://doi.org/10.1093/ofid/ofad590

Vancouver

Samra RS, Plummer EL, Vodstrcil LA, Aguirre I, Clarke EJ, Fairley CK, et al. Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance. Open Forum Infectious Diseases. 2023;10(12). doi:10.1093/ofid/ofad590

BibTeX
@article{Samra2023,
  author = {Samra, Ranjit S and Plummer, Erica L and Vodstrcil, Lenka A and Aguirre, Ivette and Clarke, Emily J and Fairley, Christopher K and Chow, Eric P F and Bradshaw, Catriona S},
  title = {Efficacy of Sitafloxacin for Mycoplasma genitalium in an Era of Increasing Antimicrobial Resistance},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {12},
  doi = {10.1093/ofid/ofad590}
}
Kostenlos starten →